Effects of continuous renal replacement therapy on refractory hypertension in maintenance hemodialysis patients

doi:10.3969/j.issn.2095-4344.2014.18.020

Abstract

Abstract:

BACKGROUND: About 10%-49% of maintenance hemodialysis patients are accompanied by refractory hypertension and common drug therapy is ineffective. Continuous renal replacement therapy could clear the middle and giant molecule toxins in the blood plasma of patients, it is theoretically treat refractory hypertension through reducing the toxin levels.
OBJECTIVE: To observe the effect of continuous renal replacement therapy on maintenance hemodialysis patients with refractory hypertension.
METHODS: A total of 45 maintenance hemodialysis patients with refractory hypertension were randomly divided into two groups, hemodialysis group (n=22) and continuous blood purification group (n=23). Hemodialysis group underwent conventional hemodialysis treatment. Continuous blood purification group underwent conventional hemodialysis therapy, and treatment of continuous blood purification weekly.
RESULTS AND CONCLUSION: After 3 months of treatment, the renin activity, endothelin, angiotensin II, C-reactive protein, interleukin-6, and tumor necrosis factor-α levels in continuous blood purification group were significantly lower than the levels before the experiment, while 24-hour mean blood pressure levels were significantly decreased (P < 0.05). In hemodialysis group, renin activity, endothelin, angiotensin II, C-reactive
protein, interleukin-6, and tumor necrosis factor-α levels and 24-hour mean blood pressure did not change (P > 0.05). After the test, continuous blood purification group showed significantly lower levels of the above index than the hemodialysis group (P < 0.05). Continuous renal replacement therapy plus hemodialysis significantly reduce the blood pressure in maintenance hemodialysis patients with refractory hypertension, the potential mechanisms are mediated by lowering the middle and giant molecule toxin as well as inflammatory factor in plasma.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: renal dialysis, hypertension, renin, angiotensin II, C-reactive protein, interleukin-6, tumor necrosis factor-alpha

CLC Number:

R318

Zhu Yuan, Zhang Xiao-dong, Song Jie, Li Hui. Effects of continuous renal replacement therapy on refractory hypertension in maintenance hemodialysis patients[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(18): 2903-2908.

Figures/Tables 2

References

[1] Takeda A, Toda T, Fujii T,et al.Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients.Am J Kidney Dis. 2005;45(1):112-118.
[2] 杨秀芹,孙玉兰.血液透析加血液灌流治疗尿毒症顽固性高血压[J].中国血液净化, 2004, 3(8): 462.
[3] Grekas D, Bamichas G, Bacharaki D,et al.Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment.Clin Nephrol. 2000;53(3): 164-168.
[4] Indra T, Holaj R, Zelinka T,et al. Left ventricle remodeling in men with moderate to severe volume-dependent hypertension.J Renin Angiotensin Aldosterone Syst. 2012; 13(4):426-434.
[5] Oltrogge KM, Peppard WJ, Saleh M,et al. Phenytoin removal by continuous venovenous hemofiltration.Ann Pharmacother. 2013;47(9):1218-1222.
[6] van den Born BJ, Koopmans RP, van Montfrans GA.The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension.Am J Hypertens. 2007; 20(8):900-906.
[7] Gonzalez-Villalobos RA, Satou R, Ohashi N,et al.Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition.Am J Physiol Renal Physiol. 2010;298(1):F150-157.
[8] Schömig M, Eisenhardt A, Ritz E.The microinflammatory state of uremia.Blood Purif. 2000;18(4):327-332.
[9] Pitsavos C, Chrysohoou C, Panagiotakos DB,et al.Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women: the ATTICA Study.Heart Vessels. 2008;23(2):96-103.
[10] 黎磊石,季大玺.连续性血液净化[M].南京:东南大学出版社, 2004: 88-94, 61, 15-30.
[11] Agarwal R, Nissenson AR, Batlle D,et al.Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.Am J Med. 2003; 115(4):291-297.
[12] Uhlig K, Levey AS, Sarnak MJ.Traditional cardiac risk factors in individuals with chronic kidney disease.Semin Dial. 2003; 16(2):118-127.
[13] Kalantar-Zadeh K, Regidor DL, Kovesdy CP,et al.Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis.Circulation. 2009;119(5):671-679.
[14] Moossavi S, Raasch E, Russell G,et al.Comparison of Dialysis Access Outcomes in Peritoneal Dialysis and Hemodialysis Patients at an Academic Medical Center.Perit Dial Int.2007;27:S24-26.
[15] Moossavi S, Coe M, Burkart J.Comparison of patient turnover/loss in an academic hemodialysis unit and peritoneal dialysis unit.Perit Dial Int.2007;27:S16-17.
[16] 夏运风,甘华.尿毒症难治性高血压的发生机制[J].山西医科大学学报, 2002,33(5):479-481.
[17] High Blood Pressure Research 2010 Scientific Sessions. Hypertension. 2010; 56: e50-e166.
[18] Navar LG, Kobori H, Prieto MC,et al. Intratubular renin-angiotensin system in hypertension.Hypertension. 2011;57(3):355-362.
[19] Minolfa C, Liu L, Alexis A, et al. Interaction of Collecting Duct-Derived Prorenin and Soluble Prorenin Receptor Increases Intraluminal Renin Activity and Augments Intratubular Angiotensin II Formation in Ang II-Dependent Hypertensive Rats. Circ. Res. 2011; 109(12): 264.
[20] Gluba A, Banach M, Mikhailidis DP, et al. Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors.In Vivo. 2009;23(5):797-812.
[21] Conti S, Cassis P, Benigni A. Aging and the Renin- Angiotensin System.Hypertension.2012;60:878-883.
[22] Zubcevic J, Waki H, Raizada MK,et al. Autonomic- immune-vascular interaction: an emerging concept for neurogenic hypertension.Hypertension. 2011;57(6):1026- 1033.
[23] Hilzendeger AM, Morgan DA, Brooks L,et al.A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity.Am J Physiol Heart Circ Physiol. 2012;303(2):H197-206.
[24] Zarzuelo MJ, Gómez-Guzmán M, Jiménez R, et al. Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension.Cardiovasc Res. 2013; 99(4):622-631.
[25] Nakamoto H, Ferrario CM, Fuller SB, et al. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension.Hypertension. 1995;25(4 Pt 2):796-802.
[26] Toda N, Okamura T.The pharmacology of nitric oxide in the peripheral nervous system of blood vessels.Pharmacol Rev. 2003;55(2):271-324.
[27] Morse SA, Dang A, Thakur V,et al. Hypertension in chronic dialysis patients: pathophysiology, monitoring, and treatment.Am J Med Sci. 2003;325(4):194-201.
[28] Pedrini LA, De Cristofaro V, Ruggiero P, et al. Hemofiltration, hemodiafiltration and other treatment modalities. Nephrol Dial Transplant. 2002; 17(7): 152-156.
[29] Marshall MR, Creamer JM, Foster M,et al.Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries.Nephrol Dial Transplant. 2011;26(7):2169-2175.
[30] Ledebo I, Blankestijn PJ.Haemodiafiltration-optimal efficiency and safety.NDT Plus. 2010;3(1):8-16.
[31] Ward RA, Schmidt B, Hullin J,et al.A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study.J Am Soc Nephrol. 2000;11(12):2344-2350.
[32] Kohlova M,Ribeiro S,Do Sameiro-Faria M,et al.Extracorporeal dialysis: techniques and adequacy II. Nephrol Dial Transplant. 2013; 28 (suppl 1): i415-i427.
[33] Christine Kubin, Amy Dzierba.The Effects of Continuous Renal Replacement on Anti-infective Therapy in the Critically Ill.Journal of Pharmacy Practice. 2005; 18(2):109-117.
[34] Maursetter L, Kight CE, Mennig J,et al. Review of the mechanism and nutrition recommendations for patients undergoing continuous renal replacement therapy.Nutr Clin Pract. 2011;26(4):382-390.
[35] Walker RJ, Sutherland WH, De Jong SA.Effect of changing from a cellulose acetate to a polysulphone dialysis membrane on protein oxidation and inflammation markers.Clin Nephrol. 2004;61(3):198-206.
[36] Ronco C, Ballestri M, Cappelli G. Dialysis membranes in convective treatments.Nephrol Dial Transplant. 2000;15 Suppl 2:31-36.
[37] Debea MK.Nanostructured Thin Film Electrocatalysts for PEM Fuel Cells - A Tutorial on the Fundamental Characteristics and Practical Properties of NSTF Catalysts.ECS Trans. 2012; 45(2):47-68.
[38] Debe MK.Tutorial on the Fundamental Characteristics and Practical Properties of Nanostructured Thin Film (NSTF) Catalysts.J Electrochem Soc. 2013;160(6): F522-F534.
[39] Ting-Yi Li, Chun-Hsien Yu, Hsin-Yan Lu,et al.Effect of Hydrophobic Tail Length of Polysorbate Surfactants on Properties of Porous Silica Ultra-Low-k Films.ECS J Solid State Sci Technol. 2013; 2(3):N61-N68.
[40] Woutersa JJ, Ladob JJ, Isabel Tejedor-Tejedora M,et al. Low Surface Area Carbon Fiber Electrodes Coated with Nanoporous Thin-Films of γ–Al2O3 and SiO2: Relationship between Coating Conditions, Microstructure and Double Layer Capacitance.J Electrochem Soc. 2012;159(8):A1374- A1382.
[41] Kestelli M, Yurekli I, Aksun M,et al. Pore size is significant in hemofiltration.Eur J Cardiothorac Surg. 2011;39(3):425.
[42] Icardi A, Paoletti E, De Nicola L,et al.Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.Nephrol Dial Transplant. 2013; 28(7):1672-1679.
[43] Kimmel M, Alscher DM, Dunst R,et al.The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.Nephrol Dial Transplant. 2006;21(3): 749-755.
[44] O'Toole SM, Fan SL, Yaqoob MM,et al. Managing diabetes in dialysis patients.Postgrad Med J. 2012;88(1037):160-166.
[45] Arteriosclerosis,Thrombosis,and Vascular Biology 2001 Scientific Sessions.Arterioscler Thromb Vasc Biol.2010;30: e183-e321.
[46] Kokturk O, Ciftci TU, Mollarecep E,et al.Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome.Int Heart J. 2005; 46(5):801-809.
[47] Bisoendial RJ, Boekholdt SM, Vergeer M, et al.C-reactive protein is a mediator of cardiovascular disease.Eur Heart J. 2010;31(17):2087-2091.
[48] Howren MB, Lamkin DM, Suls J.Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-186.
[49] Nation DA, Gonzales JA, Mendez AJ,et al.The effect of social environment on markers of vascular oxidative stress and inflammation in the Watanabe heritable hyperlipidemic rabbit.Psychosom Med. 2008;70(3):269-275.
[50] Vongpatanasin W, Thomas GD, Schwartz R,et al.C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007 ;115(8):1020-1028.
[51] Chamarthi B, Williams GH, Ricchiuti V, et al.Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans.Am J Hypertens. 2011;24(10):1143-1148.
[52] Ramseyer VD, Garvin JL.Tumor necrosis factor-α: regulation of renal function and blood pressure.Am J Physiol Renal Physiol. 2013;304(10):F1231-1242.
[53] Kovacic JC, Moreno P, Nabel EG,et al.Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly.Circulation. 2011;123(17): 1900-1910.
[54] Westenbrink BD, Ruifrok WP, Voors AA,et al.Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.Cardiovasc Res. 2010;87(1):30-39.
[55] Saban MR, Sferra TJ, Davis CA,et al.Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment.Am J Physiol Renal Physiol. 2010;299(6):F1245-1256.
[56] Fitzgerald DJ,Cecere G.Hemofiltration and inflammatory mediators.Perfusion.2002;17 Suppl:23-28.
[57] Goldfarb S, Golper TA. Proinflammatory cytokines and hemofiltration membranes.J Am Soc Nephrol. 1994;5(2): 228-232.
[58] Donadio C,Kanaki A.Extracorporeal dialysis:techniques and adequacy.Nephrology Dialysis Transplantation. 2012; 27(Supplement 2):ii197-ii226.
[59] Moossavi S, Coe M, Burkart J.Comparison of patient turnover/loss in an academic hemodialysis unit and peritoneal dialysis unit.Perit Dial Int.2007;27:S16.